Lerdelimumab
Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug developed to reduce scarring after glaucoma drainage surgery. Development was stopped in late 2005 after unsuccessful trial results.